The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
EphA2 siRNA in DOPC nanoliposomes (EPHARNA): A phase I clinical trial in patients with solid tumors.
 
Ravali Reddy
Employment - Neurocrine Biosciences (I)
 
Aung Naing
Employment - Baylor College of Medicine and Texas Children's Hospital (I); MD Anderson Cancer Center
Honoraria - AKH Inc.; American Society of Clinical Oncology; CME Outfitters; ESMO; Korean Society of Medical Oncology (KSMO); Lynx Group; Scripps Hospital; Society for Immunotherapy of Cancer
Consulting or Advisory Role - Abbvie; CytomX Therapeutics; Deka Biosciences; Genome & Company; Horizon Therapeutics (I); Immune-Onc Therapeutics; Janssen Biotech; Lynx Health; Merk Sharp & Dohme Corp; NGM Biopharmaceuticals; Nouscom; OncoSec; Pharming NV (I); PsiOxus Therapeutics; SERVIER; STCube Pharmaceuticals Inc.; Takeda (I)
Speakers' Bureau - Alfaisal University (I)
Research Funding - Amplimmune; Arcus Biosciences; ARMO BioSciences; Atterocor; Baxalta (I); BioNTech SE; Bristol-Myers Squibb; Calithera Biosciences; Chao Physician-Scientist Awards (I); CytomX Therapeutics; EMD Serono; Healios; Immune Deficiency Foundation (I); ImmuneOncia; Incyte; Jeffrey Modell Foundation (I); Karyopharm Therapeutics; Kymab; Lilly; MedImmune; Merck; Monopteros Therapeutics; NCI; NeoImmuneTech; Neon Therapeutics; Novartis; Pfizer; PsiOxus Therapeutics; Regeneron; Seven and Eight Biopharmaceuticals; Sotio; Surface Oncology; The Texas Medical Center Digestive Diseases Center (I); TopAlliance BioSciences Inc
Travel, Accommodations, Expenses - ARMO BioSciences; NeoImmuneTech; NGM Biopharmaceuticals
 
Gabriel Lopez-Berestein
No Relationships to Disclose
 
Cristian Rodriguez-Aguayo
No Relationships to Disclose
 
Hassan Momin
No Relationships to Disclose
 
Anupama Madhyannapu
No Relationships to Disclose
 
Ying Yuan
Consulting or Advisory Role - Abbvie; Amgen; Ascendis Pharma; Astellas Pharma; Bexion; Bristol-Myers Squibb/Celgene/Juno; Century Therapeutics; Century Therapeutics; GT Medical Technologies; Merck; NeoImmuneTech; NGM Biopharmaceuticals; Ono Pharmaceutical; Repare Therapeutics; Schrodinger; SERVIER; Umoja Biopharma; Vertex
 
Sarah Pasyar
No Relationships to Disclose
 
Daniel Karp
Consulting or Advisory Role - Affigen; Black Beret Life Sciences; Phosplatin Therapeutics
Research Funding - Phosplatin Therapeutics (Inst)
Travel, Accommodations, Expenses - Phosplatin Therapeutics
 
Shubham Pant
Stock and Other Ownership Interests - Teleprian
Consulting or Advisory Role - Alligator Bioscience; Arcus Biosciences; AskGene Pharma; AstraZeneca; Boehringer Ingelheim; BPGbio; Ipsen; Janssen; Jazz Pharmaceuticals; Merck; Nihon Medi-Physics; Novartis; Pfizer; Revolution Medicines; US WorldMeds
Research Funding - 4D Pharma (Inst); Amal Therapeutics (Inst); Arcus Biosciences (Inst); Astellas Pharma (Inst); bionte (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Elicio Therapeutics (Inst); Immuneering (Inst); ImmunoMET (Inst); Ipsen (Inst); Janssen (Inst); Lilly (Inst); Mirati Therapeutics (Inst); NGM Biopharmaceuticals (Inst); Novartis (Inst); Pfizer (Inst); Purple Biotech (Inst); Rgenix (Inst); Xencor (Inst); Zymeworks (Inst)
 
Sarina Piha-Paul
Consulting or Advisory Role - CRC Oncology; Lilly
Research Funding - ABM (Inst); Alkermes (Inst); Aminex (Inst); Biomarin (Inst); Boehringer Ingelheim (Inst); Bristol Myers Squib (Inst); Cancer Prevention Research Institute of Texas (CPRIT) (Inst); Chugai Pharma (Inst); Cullinan Oncology (Inst); Cyclacel (Inst); Daichi Sanko (Inst); ENB Therapeutics (Inst); Epigenetix (Inst); Genmab (Inst); Gilead Sciences (Inst); Immunity Bio, Inc. (Inst); Immunomedics (Inst); Incyte (Inst); Innovent Biologics (Inst); Jazz Pharmaceuticals (Inst); Johnson & Johnson/Janssen (Inst); Loxo (Inst); Medivation (Inst); Merck Sharp and Dohme Corp. (Inst); Nectin Therapeutics (Inst); NIH/NCI (Inst); NRG Oncology (Inst); Nurix (Inst); OncoNano Inc (Inst); Pfizer (Inst); Phanes Therapeutics (Inst); Pieris Pharmaceuticals (Inst); ProfoundBio (Inst); Puma Biotechnology (Inst); Purinomia (Inst); Replimune (Inst); Roche/Blueprint (Inst); Seagen (Inst); Strand Therapeutics, Inc. (Inst); Tallac Therapeutics, Inc. (Inst); Toragen Therapeutics, Inc. (Inst); TransThera Biosciences (Inst); ViroMissile, Inc. (Inst); Xencor (Inst)
 
Siqing Fu
Research Funding - Abbisko (Inst); BeiGene (Inst); BioAtla (Inst); Boehringer Ingelheim (Inst); CUE Biopharma (Inst); Exelis (Inst); Exelis (Inst); Greenfire Bio (Inst); Hookipa Pharma (Inst); IMV (Inst); Innovent Biologics (Inst); K-Group Beta (Inst); Lilly (Inst); Lyvgen Biopharma (Inst); MacroGenics (Inst); MediLink Therapeutics (Inst); Millennium (Inst); Nerviano Medical Sciences (Inst); NeuPharma, Inc. (Inst); NextCure (Inst); NIH/NCI (Inst); Ningbo NewBay Medical Technology (Inst); Novartis (Inst); NovoCure (Inst); Nykode Therapeutics (Inst); Parexel International, LLC (Inst); Pionyr (Inst); PureTech (Inst); Sellas Life Sciences (Inst); Soricimed (Inst); SQZ Biotech (Inst); Sumitomo Dainippon Pharma Oncology (Inst); Taiho Oncology (Inst); Treadwell Therapeutics (Inst); Turnstone Bio (Inst); Tyligand Bioscience (Inst); Virogin Biotech (Inst)
 
Apostolia Tsimberidou
Consulting or Advisory Role - Avstera; BioEclipse Therapeutics; BrYet; Macrogenics; Nex-I; Vincerx Pharma
Research Funding - Abbvie (Inst); Agenus (Inst); Anaveon (Inst); BrYet; IMMATICS (Inst); Macrogenics (Inst); Novocure (Inst); OBI Pharma (Inst); Orionis (Inst); Parker Institute for Cancer Immunotherapy (Inst); Tachyon (Inst); Tempus (Inst); Tempus (Inst); Tvardi Therapeutics (Inst); Vividion Therapeutics (Inst)
 
Robert Coleman
Employment - US Oncology; Vaniam Group
Stock and Other Ownership Interests - McKesson/US Oncology Network
Consulting or Advisory Role - Abbvie; Alkermes; Alkermes; AstraZeneca/MedImmune; Clovis Oncology; Eisai; Genentech/Roche; Genmab; GlaxoSmithKline; GOG Foundation; Gradalis; Immunogen; Karyopharm Therapeutics; Merck; Merck
Research Funding - Alkermes; AstraZeneca/MedImmune; Immunogen (Inst); Karyopharm Therapeutics (Inst); Lilly (Inst); Merck; Pfizer (Inst); Regeneron (Inst)
Travel, Accommodations, Expenses - Array BioPharma; AstraZeneca/MedImmune; Clovis Oncology; Clovis Oncology; GOG Foundation; Merck; Research to Practice; Roche/Genentech; Sotio; Vaniam Group
 
Anil Sood
Employment - Amgen (I)
Consulting or Advisory Role - Iylon; Onxeo
Patents, Royalties, Other Intellectual Property - EGFL6 antibody royalty payment; SiRNA delivery (patents on DOPC, rHDL)
Other Relationship - Advenchen Laboratories; Mural Oncology
(OPTIONAL) Uncompensated Relationships - Elsevier
 
Shannon Westin
Consulting or Advisory Role - AstraZeneca; Caris Life Sciences; Clovis Oncology; Curio Science; Daiichi Sankyo; Eisai; EQRX; Genentech; Gerson Lehrman Group; Gilead Sciences; GlaxoSmithKline; Immunocore; Immunogen; Incyte; Lilly; Loxo/Lilly; Medscape; Merck; Mereo BioPharma; Mersana; Mersana; NGM Biopharmaceuticals; Nuvectis Pharma; Nuvectis Pharma; OncLive; pharma&; Roche; Seagen; Targeted Oncology; Verastem; Vincerx Pharma; Zentalis; ZielBio
Research Funding - AstraZeneca (Inst); Avenge Bio (Inst); Bayer (Inst); Bio-Path Holdings, Inc (Inst); Clovis Oncology (Inst); Daiichi Sankyo Europe GmbH (Inst); GlaxoSmithKline (Inst); GOG Foundation (Inst); Jazz Pharmaceuticals (Inst); Loxo/Lilly (Inst); Mereo BioPharma (Inst); Novartis (Inst); Nuvectis Pharma (Inst); Pfizer (Inst); Roche/Genentech (Inst); Zentalis (Inst)